TNFRSF9 and lymphoma: Accordingly, comparing with the SpCas9-scramble group, autophagy in lymphoma cells was reduced in the SpCas9-PU.1 group treated with or without lenalidomide treatment (P = 0.002 and P < 0.001, Fig. 6f), whereas enhanced by co-treatment of PD-L1 and 4-1BB antibody (P = 0.003, Fig. 6f).